SCHEMBL3906339

SCHEMBL3906339

Cc1ccc(C(=O)NCc2c(F)cc(F)cc2F)c(NS(=O)(=O)C2=CC=CN3SNC=C23)c1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 5/20 0.34
POU2F2 P09086 3/20 0.32
TDP1 Q9NUW8 3/20 0.32
USP2 O75604 1/20 0.32
ACLY P53396 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
PKM P14618 1/20 0.31
EPHX2 P34913 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
RAB9A P51151 2/20 0.31
NPC1 O15118 1/20 0.31
MAPK14 Q16539 1/20 0.30
POLB P06746 2/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3898359 0.90 MET (0.37) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL3900397 0.90 KDM4E (0.32) ALDH1A1KDM4EPOU2F2TDP1POLB
SCHEMBL3900105 0.90 CCKBR (0.37) ALDH1A1KDM4E
SCHEMBL3897979 0.90 CCKBR (0.36) ALDH1A1KDM4EMAPT
SCHEMBL3902675 0.89 KDM4E (0.42) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL3898248 0.88 ACLY (0.39) ALDH1A1KDM4EACLYMEN1KMT2A
SCHEMBL3903033 0.86 ROCK2 (0.38) ALDH1A1KDM4EKMT2APKMEPHX2
SCHEMBL3909971 0.83 CCKBR (0.41) MAPK14
SCHEMBL3911978 0.83 CCKBR (0.40) KMT2AHPGDMAPK14MAPT
SCHEMBL3747308 0.83 ACLY (0.47) ALDH1A1KDM4EACLYMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US claimed
US-7550492-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-23 US disclosed
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 US disclosed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
EP-1675837-A2 BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-05 EP disclosed
WO-2005012275-A2 BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-10 WO disclosed
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS CCKBR, CCKAR, GIPR ALDH1A1 3254/4885KDM4E 4124/4885POU2F2 320/4885
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds CCKBR, CCKAR, BRSK2 ALDH1A1 1824/4885KDM4E 3591/4885POU2F2 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.